Guest guest Posted October 19, 2005 Report Share Posted October 19, 2005 Yes, I so much agree!! Hopefully we are the generation that will find a cure to this!!! Ingrid > > I was looking at another site and a poster mentioned TROVAX. I did a google > and found it encouraging that advances were being made for treatment-cure and > increased survival for stage 4 people. Found another area talking about good > trials for use of radioactive iodine for liver cancer. If we hang around > awhile the treatment seems to get better and better. For decades 5FU was all > there was. Being a statistics person I feel encouraged with medical progress > lately. From 2004 a whole lot of progress has been made. Be enlightened and seek > the latest and best treatment > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted October 20, 2005 Report Share Posted October 20, 2005 Products / TroVax® PRODUCT DESCRIPTION TroVax is Oxford BioMedica's leading cancer immunotherapy product. It is a novel cancer vaccine in clinical development with potential application in most solid tumour types. TroVax delivers a novel proprietary tumour associated antigen (5T4) using a pox virus vector. 5T4 is broadly distributed throughout a wide range of solid cancers and the presence of the 5T4 antigen is correlated with poor prognosis. INDICATION All solid tumours where the 5T4 tumour antigen is present. This includes colorectal, renal cell and breast cancer. MARKET Worldwide cancer vaccine revenues are estimated to reach approximately US$6 billion by 2010 (Arrowhead). TECHNICAL DESIGN Proprietary tumour associated antigen, 5T4, delivered by the pox virus vector, modified vaccinia virus Ankara (MVA). CLINICAL STATUS Over 70 patients have been treated in clinical trials with TroVax. This figure includes the completed Phase I/II trial investigating TroVax in second line treatment of late stage colorectal cancer patients who had completed chemotherapy but had slowly progressive disease. This patient group showed a very high (94%) frequency of immune response to the tumour antigen and a clear correlation between the magnitude of the immune response and both time to disease progression and overall survival. The clinical programme could see the total number of patients treated with TroVax increase to over 200 in the next 12 months. There are four Phase II trials ongoing, three in colorectal cancer and one in renal cell carcinoma. A Phase II trial in breast cancer is also expected to start later in the year. The US National Cancer Institute is supporting the breast cancer trial, at minimal cost to Oxford BioMedica. Data reported on 2 March 2005 from two Phase II trials in first line treatment of metastatic colorectal cancer with concomitant chemotherapy have confirmed previous indications that the primary endpoints of safety and immunological responses have been achieved. All patients that have reached the interim stage of the trial have shown an immune response to the 5T4 tumour antigen. In the two trials, the secondary endpoint of clinical benefit exceeded expectation. Eighteen of 19 evaluable patients responded to treatment. Whilst five patients had disease stabilisation following treatment, 13 of the 19 patients were defined as clinical responders according to industry standard criteria. Analysis of the first evaluable patients in a third Phase II trial of TroVax in colorectal cancer patients undergoing surgery for liver metastases has shown that all patients have mounted an immune response against the target tumour antigen. This investigator initiated trial is sponsored by Cancer Research UK. Oxford BioMedica and its clinical advisors are planning pivotal trials for TroVax that could start in the first half of 2006. The development strategy is designed to support initial product registration for TroVax in the United States in 2008-09. In preparation for pivotal trials and potential product registration, the manufacturing process has been upgraded for commercial production of TroVax. Oxford BioMedica contracted a major biologicals manufacturer for the successful scale-up of manufacture during 2004. The company now holds over 22,000 doses of commercial-grade material. COMMERCIALISATION STRATEGY Partners sought for clinical development and marketing. RELATED PRODUCTS AND PARTNERS Anti-cancer immunotoxin based on anti-5T4 antibody: Wyeth. Cancer imaging product based on anti-5T4 antibody: Amersham. Animal cancer vaccine TroVax-Vet®: Intervet. http://www.oxfordbiomedica.co.uk/trovax.htm Priscilla A. Savary Executive Director Colorectal Cancer Network PO Box 182, Kensington MD 20895 psavary@... www.colorectal-cancer.net _________ Screening for All. Colon Cancer for None. ProjectMARCH -- rarely in life do you get a chance to make major change or save thousands of lives. March 6, 2006 you can. http://www.colorectal-cancer.net/projectmarch.htm TROVAX I was looking at another site and a poster mentioned TROVAX. I did a google and found it encouraging that advances were being made for treatment-cure and increased survival for stage 4 people. Found another area talking about good trials for use of radioactive iodine for liver cancer. If we hang around awhile the treatment seems to get better and better. For decades 5FU was all there was. Being a statistics person I feel encouraged with medical progress lately. From 2004 a whole lot of progress has been made. Be enlightened and seek the latest and best treatment Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.